DEET: a review and update of safety and risk in the general population.
The emergence of West Nile Virus (WNV) in North America has resulted in increased public awareness and utilization of insect repellents containing N,N-diethyl-m-toluamide (DEET) in the prevention of mosquito-borne disease. Regulatory reassessments in North American countries have recently been completed for insect repellents containing DEET as active ingredient, resulting in labeling changes intended to minimize unnecessary exposure to special populations, including children. This article describes those changes, and summarizes more recent data relating to the pharmacokinetics, toxicology, and epidemiology of adverse effects associated with DEET in humans.
Sudakin
Daniel L
DL
Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, Oregon 97331-6502, USA. sudakind@ace.orst.edu
Trevathan
Wade R
WR
D000818:Animals; D001711:Biotransformation; D003671:DEET / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000633:toxicity; D004347:Drug Interactions; D005260:Female; D006801:Humans; D007302:Insect Repellents / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000633:toxicity; D007774:Lactation / Q000502:physiology; D020258:Neurotoxicity Syndromes / Q000503:physiopathology; D011039:Poison Control Centers; D011247:Pregnancy; D018570:Risk Assessment; D014481:United States; D014901:West Nile Fever / Q000517:prevention & control / Q000635:transmission
D007302:Insect Repellents; D003671:DEET